
Sign up to save your podcasts
Or


In this episode, host Laura Hart chats with Professor Amit Bar-Or (University of Pennsylvania) about the potential of the BTK inhibitor fenebrutinib in treating relapsing multiple sclerosis, highlighting future challenges in MS research.
Read the full article:
https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(25)00174-7/fulltext?dgcid=buzzsprout_icw_podcast_July_25_laneur
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
By The Lancet Group5
66 ratings
In this episode, host Laura Hart chats with Professor Amit Bar-Or (University of Pennsylvania) about the potential of the BTK inhibitor fenebrutinib in treating relapsing multiple sclerosis, highlighting future challenges in MS research.
Read the full article:
https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(25)00174-7/fulltext?dgcid=buzzsprout_icw_podcast_July_25_laneur
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

137 Listeners

322 Listeners

296 Listeners

93 Listeners

9 Listeners

49 Listeners

292 Listeners

13 Listeners

24 Listeners

136 Listeners

9 Listeners

190 Listeners

374 Listeners

83 Listeners

0 Listeners